Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
IPO Year: n/a
Exchange: NASDAQ
Website: advaxis.com
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)
SC 13D/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)
SC 13D/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)
SC 13D/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)
SC 13G/A - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)
SC 13D - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)
SC 13G - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)
SC 13G - Ayala Pharmaceuticals, Inc. (0001100397) (Subject)
SC 13G/A - Advaxis, Inc. (0001100397) (Subject)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
SUZHOU, China and ROCKVILLE, Md., April 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its appointment of Dr. David Sidransky, MD., a renowned oncologist, to the company's Board of Directors as an independent non-executive director, effective on March 31, 2021. Known for in research in biomarkers for early detection and therapy and profiled by TIME magazine in 2001 as one of America's best in science and medicine, Dr. Sidransky is a leading expert in oncology and precision medicine widely respected in the biophar
15-12G - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
10-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
8-K/A - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
10-K - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
S-8 POS - Ayala Pharmaceuticals, Inc. (0001100397) (Filer)
Data show enhanced anti-tumor activity of AL102 over time Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Company to host conference call and webcast to discuss updated Phase 2 results on Wednesday, June 7 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced further results from the Phase 2 (Part A) segment of the RINGSIDE study evaluating AL102 in desmoid tumors. The results were presented in a Poster Discussion Session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 3. AL102 is a once-daily, po
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the "Company," "New Ayala," "we," "us" or "our") (OTCQX:ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022. Management Commentary "We were pleased to close our previously announced merger in January 2023," said Kenneth A. Berlin, President and Chief Executive Officer of the Company. "Our immediate priorities include executing on Part B of the ongoing registration-enabling RINGSIDE study evaluating AL102 in desmoid tumors. We believe that AL102 has best in class potential and, if approved, m
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggress
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the "SEC") to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and to suspend its reporting obligations under Section 15(d) of the Exchange Act. The Company's obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15. Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Comp
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (NASDAQ:IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares of Immunome common stock, and Immunome assumed specified liabilities related to AL102. Ayala may also receive up to an additional $37.5 million in development and commercial milestone payments. "We are pleased that AL102 will now be advanced by the highly experienced team at Immunome," said Ken Berlin, President and
– Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month – Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announcement by Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. Earlier this month, Immunome announced that it entered into a definitive asset purchase agreement with Ayala to acquire AL102 and related drug candidate AL101. Completion of the transaction remains subject to customary clos
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 patients were enrolled. "Completion of enrollment in RINGSIDE represents a significant milestone in the development of AL102," said Kenneth Berlin, President and Chief Executive Officer of Ayala. "There has been a high-level of enthusiasm from clinical trial investigators, support staff, and patients during the enrollment of RINGSIDE. We are extremely grateful to the patients and their families, cl
– AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile – Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, to acquire AL102 and related drug candidate AL101 from Ayala. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development
BOTHELL, Wash. and MONMOUTH JUNCTION, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, to acquire AL102 and related drug candidate AL101 from Ayala. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash and $30 million in Immunome common stock (valued at 30-day VWAP as of February 1, 2024) at the closing and will pay up to an additional $37.5 million in development and commercial mi
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AL102, a Gamma Secretase Inhibitor (GSI), for the treatment of desmoid tumors (DT). AL102 is an investigational small molecule GSI, currently being evaluated in the Phase 3 RINGSIDE study in DT. Orphan drug designation is granted by the FDA to drugs and biologics intended for treatment, prevention or diagnosis of a rare disease or condition that affects fewer than 200,000 people in the U.S. at the time of designation. Desmoid tum
REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. ("Biosight"), pursuant to which Ayala acquired Biosight. The combined company will operate under the name Ayala Pharmaceuticals, Inc., and its shares will continue to trade on the OTCQX under Ayala's current ticker symbol ("ADXS"). "We are pleased to close the merger with Biosight which expands our product pipeline," said Ken Berlin, President & CEO. "We have added aspacytarabine (BST-236), a novel antimetabolite, which is in clinical development for AML and could potentially
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update. "We continue to make progress advancing our lead candidate AL102, which is being evaluated in the ongoing Phase 3 registration-enabling RINGSIDE for the treatment of desmoid t
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX:ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Society for Molecular Oncology (ESMO) Congress 2023, to be held in Madrid, Spain 20-24 October 2023. Poster Presentation DetailsTitle:Phase 2 Results from the RINGSIDE Phase 2/3 Trial of AL102 for Treatment of Desmoid TumorsPresenterProf. Robin Jones (The Institute of Cancer Research and Royal Marsden, UK)Presentation #1929PAbstract #4578 TitleAL101 therapy in patients with recurrent/metastatic (R/M) adenoid cy
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
3 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
3/A - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
3/A - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
3/A - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
4 - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
4/A - Ayala Pharmaceuticals, Inc. (0001100397) (Issuer)
Ladenburg Thalmann analyst Ahu Demir downgrades Ayala Pharmaceuticals (OTC:ADXS) from Buy to Neutral.
Upgrades Alliance Global Partners upgraded the previous rating for KNOT Offshore Partners LP (NYSE:KNOP) from Neutral to Buy. KNOT Offshore Partners earned $0.04 in the first quarter, compared to $0.79 in the year-ago quarter. The stock has a 52-week-high of $18.67 and a 52-week-low of $4.28. At the end of the last trading period, KNOT Offshore Partners closed at $4.80. Ladenburg Thalmann upgraded the previous rating for Advaxis Inc (OTC:ADXS) from Neutral to Buy. The stock has a 52-week-high of $7.20 and a 52-week-low of $0.65. At the end of the last trading period, Advaxis closed at $0.85. For ChargePoint Holdings Inc (NYSE:CHPT), B of A Securities upgraded the previous rating of Neu
Ladenburg Thalmann analyst Ahu Demir upgrades Advaxis (OTC:ADXS) from Neutral to Buy and announces $4 price target.
Ayala Pharmaceuticals Inc (NASDAQ:AYLA) and Advaxis Inc (OTC:ADXS) have announced a merger agreement. The merger would result in a combined company focusing predominantly on developing and commercializing Ayala's lead program AL102 to treat desmoid tumors and Advaxis's candidate ADXS-504 in development for prostate cancer. Ayala's lead candidate, AL102, is currently being investigated in the Phase 2/3 RINGSIDE study in desmoid tumors. The combined company has the cash to advance the combined portfolio through key milestones in 2023. Each Ayala share will be converted into the right to receive Advaxis shares. Combined Company to Seek Uplisting to Nasdaq. Upon completion of the merger
Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers and Advaxis, Inc. (OTCQX:ADXS) (Advaxis), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes, today announced that they have entered into a definitive merger agreement. The merger would result in a combined company that will focus predominantly on the development and commercialization of Ayala's lead program AL102 for the treatment of desmoid tumors and Advaxis
-SEC Filing
Updated data show a second partial response in Part B Overall response rate of 15.4% and disease control rate of 46% in Part B with durable clinical benefit in patients with prior disease progression Preliminary data show disease control rate of 67% in first 3 patients in Part C, with ADXS-503 being dosed in combination with pembrolizumab in first line MONMOUTH JUNCTION, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced updated data from the Company's ongoing Phase 1/2 study evaluating ADXS-503 in combination with KEYTRUDA®. ADXS-503 is th
Gainers BioCardia (NASDAQ:BCDA) shares rose 29.91% to $2.91 during Wednesday's after-market session. At the close, BioCardia's trading volume reached 793.9K shares. This is 471.05% of its average volume over the last 100 days. The company's market cap stands at $49.0 million. AnPac Bio-Medical Science (NASDAQ:ANPC) shares moved upwards by 8.91% to $1.1. The market value of their outstanding shares is at $19.5 million. BioSig Technologies (NASDAQ:BSGM) shares rose 5.19% to $2.43. The market value of their outstanding shares is at $85.8 million. Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 4.71% to $2.0. The company's market cap stands at $16.6 million. Evoke Pharma (NASDAQ:
Stockholders approved Proposal 1 in support of Biosight merger Proposal 2 reverse stock split, a condition for completing the merger of Advaxis and Biosight, was not approved MONMOUTH JUNCTION, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that following the conclusion of its second reconvened special meeting of stockholders on December 16, 2021, it plans to continue to explore additional options to maximize stockholder value. The Company’s Proposal 2 to authorize a reverse stock split, a condition to consummating the Company’s agreed up